Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Boehringer Ingelheim (Germany) · University Hospital of Basel · +1 more institution
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic pathways involved in IPF have not been fully elucidated, IPF is believed to be caused by repetitive alveolar epithelial cell injury and dysregulated repair, in which there is uncontrolled proliferation of lung fibroblasts and differentiation of fibroblasts into myofibroblasts, which excessively deposit extracellular matrix (ECM) proteins in the interstitial space. A number of profibrotic mediators including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and transforming growth factor-β are believed to play…
Citation impact
- FWCI
- 39.77
- Percentile
- 100%
- References
- 95
Authors
7Topics & keywords
- Nintedanib
- Idiopathic pulmonary fibrosis
- Medicine
- Platelet-derived growth factor receptor
- Hepatocyte growth factor
- Fibrosis
- Cancer research
- Extracellular matrix
- Good health and well-being